There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atara Biotherapeutics (ATRA) and Audentes Therapeutics (BOLD) with bullish sentiments.
Atara Biotherapeutics (ATRA)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics today and set a price target of $62. The company’s shares closed on Friday at $36.05.
Syed noted:
“an NDR. We were joined by Dietmar Berger (Global Koppikar (CFO), and John Craighead (Vice President, Investor Relations & Corporate Communications). Immediately following our ATRA NDR was our Tour, where we had the privilege of visiting the Manufacturing (ATOM) facility in Thousand Oaks, CA. For the ATOM tour, we were joined by Joe Newell (EVP & Valko (SVP, Vidal (SVP, Bolish (Manufacturing Zimmerman (Supply Chain) & Rhine Shen (Preclinical and Translational Science).”
According to TipRanks.com, Syed is a 1-star analyst with an average return of -1.1% and a 46.7% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Wave Life Sciences, and Gilead Sciences.
Atara Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $66, which is an 83.1% upside from current levels. In a report issued on April 1, William Blair also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Audentes Therapeutics (BOLD)
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Audentes Therapeutics, with a price target of $45. The company’s shares closed on Friday at $40.32.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 14.1% and a 44.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.
Audentes Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $48.20, which is a 19.5% upside from current levels. In a report issued on April 8, Piper Jaffray also reiterated a Buy rating on the stock with a $55 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
